HIF-2α inhibition may regulate the recruitment of Tregs to the glioma site through a reduction of Treg-attracting chemokines such as CCL17, CCL22, and CCL18 or a re-polarization of the pro-tumoral macrophages secreting these factors [67]. The gene discussed is CCL18; the disease is central nervous system cancer.